Shamburg News · 8-K filed Nov 16, 2026, 7:20 AM EST
MapLight Therapeutics Reports Third Quarter 2026 Results and Business Update
MPLT · MapLight Therapeutics, Inc.
- Earnings
- Reg FD disclosure
- Materiality: high
MapLight Therapeutics reported a third-quarter 2026 net loss of $51.6 million, compared with $29.4 million a year earlier, and R&D expenses of $44.2 million. The company ended the quarter with $463.4 million in cash, cash equivalents and investments, which it expects to fund operations through 2028. The release also updated the ZEPHYR-2 Phase 3 and VISTA Phase 2 trial timelines for ML-007C-MA; no EPS guidance or adjusted EPS was reported.
Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, 9.01, accession 0001193125-26-462061.
Written from the filing by Shamburg Markets. Figures are as reported by the company.